MIMEDX GROUP, INC. (NASDAQ:MDXG) Files An 8-K Results of Operations and Financial ConditionItem 2.02Other
On January 7, 2018, MiMedx Group, Inc. (the “Company”) issued a press release providing certain preliminary financial results for the period ended December 31, 2017, as well as certain other matters.A copy of the press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.The information provided to Item 2.02 of this Form 8-K is to be considered “furnished” and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.
Item 9.01Financial Statements and Exhibits
(d)Exhibits
MIMEDX GROUP, INC. ExhibitEX-99.1 2 a8-kexhibit9911082018x01.htm PRESS RELEASE Exhibit Exhibit 99.1PRESS RELEASE Contact: Michael SenkenPhone: (770) 651-9100MiMedx Releases Preliminary 2017 Revenue of $324.5 Million representing a 32% increase over 2016 Fourth Quarter 2017 Preliminary Revenue of $90.9 Million Surpasses upper Range of Q4 guidance by Nearly $3 millionMarietta,…To view the full exhibit click here
About MIMEDX GROUP, INC. (NASDAQ:MDXG)
MiMedx Group, Inc. (MiMedx) is an integrated developer, processor and marketer of regenerative biomaterial products and bioimplants processed from human amniotic membrane and other birth tissues and human skin and bone. The Company operates in the Regenerative Biomaterials business segment, which includes the development, processing and marketing of regenerative biomaterial products and bioimplants processed from human amniotic membrane and other birth tissues in the wound care, surgical, sports medicine, ophthalmic and dental market categories. Its biomaterial platform technologies are AmnioFix, EpiFix, OrthoFlo, Physio, AlloBurn, and CollaFix. AmnioFix and EpiFix are its tissue technologies processed from human amniotic membrane derived from donated placentas. The Company processes the human amniotic membrane utilizing its PURION Process, to produce an implant. MiMedx is the supplier of amniotic tissue, having supplied over 500,000 allografts.
